Vivani Medical is developing an implant of semaglutide, the active ingredient in Novo Nordisk's obesity injection Wegovy and diabetes counterpart Ozempic.
Michael Siluk | UCG | Universal Images Group | Getty Images
Losing weight with GLP-1 drugs is only half the battle. Keeping it off long term has proved even harder.
Factors such as side effects, high out-of-pocket costs, injection fatigue and stigma ... [12795 chars]